COST-UTILITY ANALYSIS OF GEFITINIB AND EGFR MUTATION TESTING AS THE FIRST-LINE TREATMENT FOR NON-SMALL CELL LUNG CANCER IN VIETNAM

被引：0
|
作者：
Tran, T. T. [1 ]
机构：
[1] Univ Tsukuba, Tsukuba, Ibaraki, Japan
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 05期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN143
引用
收藏
页码：A112 / A112
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness analysis of EGFR mutation testing and gefitinib as first-line therapy for non-small cell lung cancer
    Narita, Yusuke
    Matsushima, Yukiko
    Shiroiwa, Takeru
    Chiba, Koji
    Nakanishi, Yoichi
    Kurokawa, Tatsuo
    Urushihara, Hisashi
    [J]. LUNG CANCER, 2015, 90 (01) : 71 - 77
  • [2] COST-UTILITY ANALYSIS OF FIRST-LINE GEFITINIB, ERLOTINIB AND AFATINIB IN PATIENTS WITH NON-SMALL CELL LUNG CANCER HARBORING EGFR MUTATIONS
    Holleman, M. S.
    Zaim, R.
    Uyl-De Groot, C. A.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A740 - A741
  • [3] Cost-utility of afatinib and gefitinib as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer
    Wang, Hao
    Zeng, Chenxin
    Li, Xin
    Wang, Youjie
    Li, Xinyi
    Ge, Weihong
    [J]. FUTURE ONCOLOGY, 2019, 15 (02) : 181 - 191
  • [4] First-line treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC) by gefitinib
    Moiseyenko, V.
    Procenko, S. A.
    Levchenko, E. V.
    Barchuk, A. S.
    Matsko, D. E.
    Moiseyenko, F. V.
    Ivantsov, A. O.
    Iyevleva, A. G.
    Mitiushkina, N. V.
    Imyanitov, E. N.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [5] COST-UTILITY ANA LYSIS OF ERLOTIB VERSUS STANDARD CHEMOTHERAPY IN FIRST-LINE TREATMENT OF ADVANCED EGFR MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER IN VIETNAM
    Tran, T. T.
    Nguyen, T.
    [J]. VALUE IN HEALTH, 2016, 19 (03) : A154 - A154
  • [6] Cost-Utility Analysis of First-Line Pemetrexed Plus Cisplatin in Non-Small Cell Lung Cancer in Thailand
    Permsuwan, Unchalee
    Thongprasert, Sumitra
    Sirichanchuen, Buntitabhon
    [J]. VALUE IN HEALTH REGIONAL ISSUES, 2020, 21 : 9 - 16
  • [7] COST-UTILITY ANALYSIS OF LORLATINIB FOR FIRST-LINE TREATMENT FOR ALK POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER IN CHINA
    He, X.
    Fu, S.
    [J]. VALUE IN HEALTH, 2023, 26 (12) : S63 - S63
  • [8] Audit of gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer in patients with EGFR mutation
    Douglas, R.
    Campbell, L.
    McAleese, J.
    Scullin, P.
    [J]. LUNG CANCER, 2013, 79 : S9 - S9
  • [9] Study of Gefitinib and Pemetrexed as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation
    An, Chaolun
    Zhang, Jiajun
    Chu, Hongjun
    Gu, Chunyan
    Xiao, Feng
    Zhu, Fengwei
    Lu, Rujian
    Shi, Hai
    Zhang, Hongfei
    Yi, Xin
    [J]. PATHOLOGY & ONCOLOGY RESEARCH, 2016, 22 (04) : 763 - 768
  • [10] ECONOMIC EVALUATION OF GEFITINIB FOR FIRST-LINE TREATMENT OF EGFR MUTATION POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS IN GREECE
    Fragoulakis, V
    Pallis, A.
    Kourlaba, G.
    Georgoulias, V
    Maniadakis, N.
    [J]. VALUE IN HEALTH, 2011, 14 (07) : A454 - A454
12345